Introduction {#s1}
============

Alzheimer's disease (AD), particularly its sporadic or late-onset form (SAD/LOAD), is by far the most prevalent cause of senile dementia in humans ([@B1]). Typically, multiple neurotoxic factors accumulate in the AD brain, such as soluble amyloid-β oligomers (sAβ-os) and insoluble Aβ fibrils (fAβs), the latter aggregating into senile plaques ([@B133]); hyperphosphorylated soluble Tau oligomers (p-Tau-os) that collect into insoluble neurofibrillary tangles (NFTs) ([@B27]); overproduced reactive oxygen species (ROS) ([@B43]); nitric oxide (NO); vascular endothelial growth factor-A (VEGF-A), and proinflammatory agents ([@B87]; [@B63]). Altogether, these neurotoxins cause a spreading neuroinflammation, progressive synaptic losses, and cortical human neurons and oligodendrocytes deaths with the consequent breaking up of neural circuits. The clinical counterparts of AD neuropathology are steadily worsening losses of memories and cognitive abilities, which inexorably lead to patients' demise ([@B89]; [@B90]; [@B46]).

Amyloid precursor protein (APP), a multifunctional protein widely expressed in the central nervous system (CNS), represents the source of the neurotoxic sAβ-os and fAβs that progressively accumulate in AD brains. Transmembrane APP holoprotein can undergo alternative enzymatic handling: (i) *nonamyloidogenic processing* (*NAP*) by α-secretases that leads to the production of the soluble (s)APP-α while obstructing Aβs synthesis ([@B65]; [@B277]) ([**Figure 1**](#f1){ref-type="fig"}); and (ii) *amyloidogenic processing* (*AP*) by β-secretase (BACE1) and γ-secretase liberating Aβs ([**Figure 2**](#f2){ref-type="fig"}). Notably, sAPP-α's physiological roles are multifaceted, and to-date only partly understood. The available evidence reveals that sAPP-α promotes the neural differentiation of human embryo stem cells ([@B115]) and protects hippocampal neurons from the harm due to ischemia ([@B303]), glucose deficiency ([@B117]), brain trauma, and excitotoxicity ([@B211]; [@B129]). In addition, sAPP-α complexes with and inhibits the activity of BACE1/β-secretase protein thus hindering any excess production of toxic Aβ~42~/Aβ~42~-os ([@B308]; [@B244]; [@B259]). Moreover, sAPP-α stimulates axonal outgrowth ([@B247]), synaptogenesis, and synaptic plasticity ([@B152]; [@B142]). Remarkably, sAPP-α also curbs the activity of glycogen synthase kinase (GSK)-3β and the hyperphosphorylation and overrelease of neurotoxic p-Tau/p-Tau-os, the main components of NFTs ([@B93]). And an increased activity of GSK-3β has been linked to hyperphosphorylation of Tau in the brains of AD patients. Typically, in AD Tau is phosphorylated at over 30 serine/threonine residues by various protein kinases, including GSK-3β ([@B256]). The D1 and D6a domains of sAPP-α are the locations of its neuroprotective and neurotrophic activities since they stimulate axons outgrowth when added as separate fragments to *in vitro* hippocampal neurons ([@B168]; [@B269]; [@B247]). In keeping with such findings, sAPP-α upholds cognition and memory integrity in animal models of physiological aging and of AD ([@B280]; [@B217]; [@B29]; [@B278]; [@B81]; [@B336]) ([**Figure 1**](#f1){ref-type="fig"}).

![The *nonamyloidogenic processing* (*NAP)* of amyloid precursor protein (APP) holoprotein. By itself, APP holoprotein is not neurotoxic and is cleaved at three different locations by α- or β- and/or γ-secretase. Proteolytic cleavage by α-secretase represents the *NAP* of membrane-inserted APP holoprotein. *NAP* occurs just within the amino acid sequence of Aβ~42~, whose synthesis it consequently obstructs. Thus, α-secretase activity (mostly due to ADAM10) sheds from APP holoprotein the soluble (s)APP-α peptide, whose multiple neurotrophic and neuroprotective effects are summarized in this figure. Recent evidence indicates that as a GABA~B~1aR agonist sAPP-α also constitutively moderates neuronal excitability thus preventing neurons' harm. In summary, APP holoprotein's *NAP* hinders the development of AD and preserves neuronal viability, trophism, and function.](fphar-10-01282-g001){#f1}

![The *amyloidogenic processing (AP)* of amyloid precursor protein (APP) holoprotein. In this pathway β-secretase/BACE1 and γ-secretase sequentially cleave APP holoprotein yielding several Aβ peptide isoforms. The two most prevalent Aβ isoforms are the 40- and 42-amino acid-long residues, the length of which is determined by the cleavage site of the γ-secretase. Under physiological conditions the synthesis of monomeric neurotrophic Aβ peptides is very limited. However, when over produced Aβ peptide monomers end up aggregating first into soluble oligomers (Aβ-os), the first Alzheimer's disease (AD) drivers, next into insoluble fibrils, and eventually into senile plaques. The latter can both take up and release the neurotoxic Aβ-os. The Aβ~42~ isoform is the main component of senile plaques as is it highly prone to oligomeric and polymeric (fibrillar) aggregation. The Aβ-os interact with several nerve cell membrane receptors, including the calcium-sensing receptor (CaSR). Notably, CaSR-bound Aβ-os trigger a complex set of intracellular signals that promote the development and progression of AD neuropathology (see [**Figure 3**](#f3){ref-type="fig"} for further details).](fphar-10-01282-g002){#f2}

SAD/LOAD, which comprises ∼98--96% of the cases, starts from neuronal nests in the layer II of the lateral entorhinal cortex (LEC) in the temporal lobe ([@B179]) where small ischemic areas may occur in aged subjects ([@B161]). Thence, in the course of 20--40 years (*asymptomatic stage*) SAD/LOAD silently spreads to wider and wider upper cerebral cortex areas, particularly to those involved in storage and retrieval of memories and in handling complex cognitive activities ([@B179]). When the unremitting attrition depletes the cortical human neurons' functional reserve, SAD/LOAD's first clinical symptoms start manifesting as amnesias. This marks the onset of the *amnestic minor cognitive impairment* or *aMCI stage* that lasts 3--5 years while its symptoms progressively worsen. Eventually, the *full symptomatic stage* takes over, whose exacerbating symptoms include permanent losses of short-term (first) and long-term (later) memories, changes in personality and behavior, loss of the several language-related abilities, failure to cope with daily tasks and needs, motor problems, cognitive shortfalls, dementia, and eventually death. However, it is still hard to diagnose the earliest asymptomatic stage of AD because specific biomarkers are few and the highly neurotoxic, synapse-destroying sAβ~42~-os are hardly detectable when senile plaques and NFTs are still absent ([@B294]; [@B295]; [@B111]; [@B182]; [@B89]). Even so, the ghostly sAβ~42~-os eventually cause a noticeable accumulation of Aβ~42~ as fibrils and senile plaques, and of p-Tau-os as NFTs ([@B215]). Presently, the diagnosis of SAD/LOAD is based upon detecting brain deposits of insoluble Aβs (senile plaques) *via* PET imaging and specific changes in Aβ~42~/Aβ~40~ and Tau/p-Tau ratios values in the cerebrospinal fluid (CSF), which are deemed to be pathognomonic ([@B213]). PET imaging can also detect the brain accumulation of NFTs ([@B143]). The quest of blood biomarkers of AD is still ongoing with some preliminary promising results ([@B225]; [@B227]; [@B250]).

Presently, no drug therapy modifies or mitigates AD's relentless course ([@B166]). This unsatisfactory situation still lingers because of various reasons. First, SAD/LOAD pathogenesis remains unclear and, hence, an open to speculation topic. Second, animal models closely mirroring human SAD/LOAD are as yet not available ([@B4]). Transgenic (*tg*) animal (mostly rodent) AD-models only partially and imperfectly emulate the early-onset familial (EOF)AD variety, which comprises at most 2--4% of AD cases. It is well established that EOFAD results from mutations in the amyloid precursor protein (*APP*) or presenilin1 (*PSEN1*) or presenilin2 (*PSEN2*) genes. These mutations drive a constitutive, diffuse intrabrain overproduction and overload of sAβ-os, insoluble Aβ fibrils, and hence Aβ-heaped senile plaques and concurrently of p-Tau-os and NFTs. Conversely, no genetic mutations underlie SAD/LOAD pathogenesis, although *APOE* ([@B159]) and *TREM2* ([@B121]) gene variants could increase AD proclivity. While Aβ-os appear as the first main AD drivers, in such *tg* AD-model animals p-Tau accumulates as NFTs later and only when a mutated *MAPT* transgene is inserted too ([@B245]; [@B72]). *Third*, AD-model rodent brains substantially differ under several cytological, structural, and functional standpoints from the human brain. Some differences are obvious, such as brain size and weight, the cerebral cortex limited extent, the largely prevailing primitive olfactory cortex, and so on. Other differences are more subtle, but still exceedingly important, as they critically regard a genetic homology of only 80% and structural and functional features of cortical neurons and neuroglial cells\--e.g. the total absence of some human cortical astroglial subtypes from rodent brain cortices\--and the dissimilar extension of the astrocytes' domains, and the unlike reactions (e.g. Ca^2+^ fluxes) of each neural cell type once exposed to AD-driving neurotoxins. As a revealing example, in *tg* AD-model animals, the cortical astrocytes die sooner than neurons, whereas cortical neurons die earlier than astrocytes in human AD brains. Altogether, such a complex set of divergences has suggested that *tg* rodent AD-model animals may not be the ultimate means to identify therapeutic approaches benefiting human AD patients ([@B273]). Hitherto, all drugs that resulted advantageous when given to *tg* AD-model animals have failed to act as beneficial therapeutics in human AD patients ([@B84]). It should be noted that this is a currently recognized general problem affecting the quest for and successful trial of novel drugs preclinically tested in animal models of other human diseases besides AD ([@B118]). Unquestionably, novel rodent and non-human primate (NHP) AD models are under development ([@B266]; [@B290]) but their potential worth for human AD therapeutic research remains to be assessed.

So, are there acceptable alternatives to AD-model animals? Given the just mentioned species-related differences, one should take stock of untransformed human neural cells making up "*preclinical AD models in Petri dishes*". An example of this kind may be neural cells differentiated from human induced pluripotent stem cells (iPSCs) isolated from normal subjects and/or from EOFAD and SAD/LOAD patients and set into 2D or 3D cultures ([@B181]). Human iPSC models are easier to handle than NHP models and may also be integrated into mouse AD models ([@B107]).

Still another suitable preclinical human AD model *in vitro* consists of untransformed cortical adult human astrocytes and/or neurons. Human astrocytes from the temporal lobe cerebral cortex exhibit a stable ("*locked-in*") differentiated phenotype and give reproducible responses when exposed to fAβs and/or sAβs. The experimental exploitation of the latter cells has revealed that exogenous Aβs specifically bind the calcium-sensing receptor (CaSR) ([@B87]; [@B88]; [@B90]), a member of family C G-protein coupled receptors (GPCR), and activate a pathological signaling that could drive human LOAD/SAD onset and progression and also worsen EOFAD's course. These findings have clearly pointed out to a class of therapeutic agents, the CaSR negative allosteric modulators (NAMs), which effectively block all such AD's pathogenetic mechanisms in untransformed cortical human neurons and astrocytes *in vitro* and could stop the progression of AD neuropathology in the patients ([@B7]; [@B64]; [@B65]).

Family C GPCRs also include the metabotropic glutamate (mGlu) and GABA~A/B~ receptors ([@B30]; [@B322]). Results of studies in animal model suggest that mGlu-Rs and GABA-Rs might also be involved in AD pathophysiology because AD concurs with alterations of glutamatergic transmission ([@B50]). Therefore, we discuss here the roles of family C GPCRs in AD progression and hence their potential relevance to human AD therapy.

Family C G-Protein-Coupled Receptors {#s2}
====================================

In general, GPCRs are among the most numerous groups of transmembrane proteins of the mammalian genome. To date, about 800 of these proteins have been identified in humans ([@B114]). The relevance of their manifold functions has made them therapeutically attractive as shown by the fact that they are the targets of ∼34% of United States Food and Drug Administration-approved drugs ([@B147]). Currently, GPCRs are distinguished into six classes (families A--F) ([**Table 1**](#T1){ref-type="table"}) based upon amino acid sequence homologies, elected signal transduction pathways, and pharmacological outlines.

###### 

G-Protein-coupled receptors (GPCRs) Families.

  ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family A   rhodopsin-like receptors
  Family B   secretin receptors
  Family C   γ-aminobutyric acid B (GABA~B~) receptors; metabotropic glutamate receptors (mGluR1-8); calcium-sensing receptor CaSR; taste receptors 1-3; \*V2 pheromone receptors; \*GPRC6A receptor;\*\*various orphan receptors.\*\*
  Family D   fungal mating pheromone receptors
  Family E   cyclic AMP receptors
  Family F   frizzled/smoothened receptors
  ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*These receptors abound in rodents but are absent from humans

([@B240]; [@B3]).

\*\*Not considered in this review.

Details concerning the structure of family C GPCRs are known for the mGluRs ([@B188]; [@B318]; [@B224]; [@B97]; [@B335]), GABA~B~R ([@B125]), and CaSR ([@B120]; [@B126]) extracellular domains (ECDs), and for the mGluRs and CaSR transmembrane domains ([@B97]). Family C GPCRs share a common general structure characterized by a huge bilobed N-terminal extracellular domain (ECD) or "Venus Flytrap" (VFT) ([@B114]; [@B189]; [@B284]). A cysteine-rich region (CR) links the ECD/VFT to the 7TM domain including seven transmembrane helical hydrophobic regions (TM1--TM7) connected extracellularly by three loops (ECL1--ECL3) and intracellularly by three loops (ICL1--ICL3). The CR domain is extant in all family C GPCRs save for GABA~B~Rs. Finally, the 7TM domain is linked to the intracellular C-terminal domain (ICD), whose tail interacts with G proteins to activate downstream signaling pathways.

Family C GPCRs function as mandatory dimers ([@B105]) joined by a disulfide bond topping the two VFTs. GPCRs can be formed into homodimers or into heterodimers with other members of the same group or family ([@B131]; [@B99]; [@B172]; [@B297]) or with extraneous GPCRs ([@B71]; [@B120]; [@B44]; [@B183]). The orthosteric ligands bind the pockets placed in the slit between the two VFT's lobes causing the active closure of both slits (closed-closed conformation) or of only one slit (open-closed conformation) ([@B255]). Conformational changes inside the VFT domains are conveyed through the cysteine-rich and 7TM regions to the ICD domain to regulate G-proteins binding and activate intracellular signals ([@B282]).

The family C GPCRs subtype specificity of orthosteric agonists and antagonists varies because the amino acid sequence of the VFT binding pocket may or may not be extensively conserved. Group III mGluRs are an example of the former case, as their orthosteric agonists and antagonists are possessed of a mostly unchanging broad-spectrum activity ([@B206]; [@B10]). To overcome this obstacle to therapeutic applications, an active quest has been and still is going on for drugs that bind on particular amino acid sequences defined as allosteric sites or pockets (e.g. on the ECL1--ECL3 of the 7TM domain) and placed well outside the VFT-inside orthosteric site. A number of allosteric sites located within the 7TM domain were identified by investigations using site-directed mutagenesis and allosteric modulator cocrystal methods ([@B135];[@B97]; [@B335]; [@B68]). These novel drugs selectively modify the receptor signaling triggered by an orthosteric ligand acting as either positive allosteric modulators or PAMs or negative allosteric modulators or NAMs ([@B106]). PAMs favor whereas NAMs hinder the binding affinity/activity (the so-called cooperativity) of orthosteric ligands. Finally, neutral allosteric ligands (NALs) bind their sequence on a receptor but do not change the cooperativity of its orthosteric ligand ([@B334]; [@B69]). The otherwise steady structural conformation of orthosteric ligand-bound GPCRs undergoes transient changes, which impact on the interactions with G proteins or other transducers, when the receptors also bind allosteric modulators ([@B47]). Lipophilic PAMs and NAMs cross the blood--brain barrier (BBB) ([@B279]). However, extremely lipophilic PAMs and NAMs may exhibit a lesser ability to reach the neural cells while their unwanted side effects may become stronger ([@B132]). Present-day methods used to evaluate allosteric interactions, i.e. functional and radio-ligand binding assays, need proper probes to reveal the receptor's response and fully disclose the allosteric ligand's properties ([@B267]; [@B149]). The affinity and effectiveness of allosteric modulators can be quantified *via* the allosterism's operational model that associates the allosteric ternary complex model (ATCM) with Black--Leff's operational model of pharmacological agonism ([@B26]; [@B104]; [@B191]; [@B212]). The latter allows to quantify the modulator's effectiveness and its impact on orthosteric agonist affinity vs. efficacy ([@B26]; [@B191]; [@B177]; [@B135]). Classically, NAMs and PAMs are effective only when the natural orthosteric ligands (or probes) are present ([@B78]). At times, surrogate orthosteric probes are required for functional assays. Probes of different chemical nature may affect the cooperativity in opposite directions or leave it unchanged ([@B184]; [@B323]; [@B296]). Remarkably, allosteric modulators evoke saturable effects, i.e. no further activity obtains when they reach saturating doses ([@B212]; [@B182]). Specific PAMs and NAMs may or sometimes may not elicit the internalization of their receptors, and hence may or may not desensitize the cells to corresponding orthosteric ligands ([@B78]). Some PAMs and NAMs are of a mixed type acting as both orthosteric agonists and PAMs, while others act as both agonists for one receptor subtype and as antagonists for another receptor subtype. Preferred PAMs or NAMs should not permanently activate or inactivate the involved receptors because this could elicit harmful effects ([@B54]). Clearly, receptor subtype-specific PAMs and NAMs are indispensable tools for basic and preclinical pharmacological research and, when beneficial, might be transformed into drugs apt for clinical trials. For example, one chemokine receptor-5 NAM, i.e. Maraviroc, successfully reached the clinical use to treat late-stage HIV disease ([@B98]).

Here, a cautionary note is in order about the interspecies translatability of experimental results related to family C GPCRs. In fact, brain locations of the same family C GPCRs can significant vary between animal species (e.g. mouse vs. rat) and between animals and humans. Such species-related divergences could explain the inconsistent observations one may make when experimenting with more than one animal species. This is a further drawback to translating the beneficial effects evoked by orthosteric agonists/antagonists or allosteric PAMs/NAMs in animal models of diseases into beneficial therapeutic upshots in disease-matching human patients. Moreover, one should not overlook another caveat concerning the extrapolation to postnatal life of results gained by administering PAMs or NAMs to animal embryo-fetal cellular models. In fact, during development mGluRs expression undergoes divergent changes in distinct types of cells. Finally, on a positive note, the combined administration of orthosteric agonists or antagonists with NAMs or PAMs can provide additive or synergistic neuroprotection, which might have future therapeutic applications ([@B326]; [@B22]).

GaBA~B~Rs, APP, Aβs, and AD {#s3}
===========================

There are two classes of GABARs, i.e. GABA~A~Rs and GABA~B~Rs. While GABA~A~Rs are fast-acting ionotropic receptors functioning as ligand-gated ion channels, GABA~B~Rs are metabotropic family C GPCRs, whose structure comprises the subunits R1a, R1b, and R2 ([@B56]). Receptor dimerization or oligomerization is obligatory for GABARs as it impacts on function. Only GABA~B~ R1a/R2 or R1b/R2 heterodimers do reach the cell surface, bind GABA to R1 subunit, and activate G-protein-mediated intracellular signals *via* R2 subunit ([@B329]; [@B210]; [@B209]). Of note, GABA~B~R1 and R2 subunits form heterodimers also with the CaSR (this topic will be further discussed below). Two "*sushi domains* (SDs)" abut from the N-terminus of GABA~B~R1a VFT, which are required for the receptor's trafficking to the cell surface and for its presynaptic inhibitory activity ([@B124]; [@B146]). Adaptor proteins link the GABA~B~R1a SD1 domains to axoplasmic kinesin-1 motors. Recently, proteomic methods permitted to identify three adaptor proteins playing this role, i.e. APP, adherence-junction associated protein 1 (AJAP-1), and PILRα-associated neural protein (PIANP). Thus, axonal trafficking cargo vesicles carry at least three distinct types of GABA~B~R1a/adaptor protein/kinesin-1 complexes. It is noteworthy that the formation of any of such GABA~B~R1a/APP/kinesin-1 complexes obstructs the amyloidogenic processing (*AP*) of the involved APP molecules into Aβ~42~/Aβ~42~-os, the AD main drivers. This could be a novel AD-preventing mechanism involving GABA~B~R1a axonal trafficking ([@B96]).

Neurons express GABA~B~Rs on both presynaptic and postsynaptic membranes. Neuronal activity controls GABA~B~Rs presynaptic expression ([@B140]; [@B314]; [@B248]). Conversely, model animals of AD ([@B70]; [@B163]) and of various other diseases, like chronic epilepsy ([@B315]), fragile X syndrome ([@B173]), and Parkinson disease ([@B28]), downgrade GABA~B~Rs expression and inhibitory function causing neuronal hyperexcitability. Human astrocytes express both GABA~A~Rs and GABA~B~Rs and constitutively synthesize and release GABA, therefore being GABAergic cells. GABA release from human astrocytes is dose-dependently increased by glutamate or by NMDAR coagonists like D-serine and glycine. Conversely, inhibitors of kainic acid receptors and of NMDARs decrease GABA release from human astrocytes. Interestingly, the administration of exogenous GABA suppresses the proinflammatory responses of activated astrocytes and microglia to noxious stimuli ([@B197]; [@B198]).

The GABA~B~Rs classical ligand is γ-aminobutyric acid (GABA), which is the chief inhibitory neurotransmitter of the mature central nervous system (CNS) of vertebrates. GABA-releasing (GABAergic) neurons are ubiquitous in the CNS. Nearly half of all CNS synapses express some GABA~B~Rs and thus respond to GABA ([@B202]). The signaling activated by the GABA•GABA~B~R complexes inhibits the release of neurotransmitters from the targeted postsynaptic neurons ([@B21]; [@B25]). But the signaling activated by the presynaptic GABA•GABA~B~R complexes of the GABAergic neurons blocks their further GABA release thus acting as a physiological self-controlling mechanism exerting an indirect excitatory effect on postsynaptic neurons. An astrocyte → neurons metabolic cycle upkeeps the neuronal stores of GABA ([@B205]; [@B214]). The released GABA moieties are taken up by both pre- and postsynaptic neurons and by the astrocytes enveloping tripartite synapses. In their mitochondria, the astrocytes convert the uptaken GABA into glutamine and forward the glutamine to adjoining neurons. In presynaptic neurons, two sequentially acting enzymes synthesize GABA from glutamine: first, glutaminase, which converts glutamine into glutamate; and second, glutamic acid decarboxylase (GAD), which transforms glutamate into GABA. Next, the vesicular transporter of GABA (VGAT) transfers it into cargo/synaptic vesicles, which release GABA into the synaptic cleft after the neuron's membrane depolarization. GABA signaling regulates several physiological aspects of CNS activity, like neurogenesis, neuronal development, sexual maturation, circadian rhythms, motor functions, learning, and memory ([@B262]). GABAergic interneurons are the chief inhibitory neurons in the CNS. Abundant reports in the literature stress how dysfunctions of the activity of GABAergic interneurons disrupt the glutamatergic excitatory/GABAergic inhibitory (E/I) balance in neural circuits of the cerebral cortex, hippocampus, and subcortical structures (e.g. amygdala) causing declining cognitive capabilities and worsening memory losses. Therefore, it is generally held that E/I imbalance significantly impacts on the pathogenesis of AD ([@B134]; [@B327]) and of various other CNS disorders, such as major depression ([@B109]), schizophrenia, autism's spectrum, bipolar disorder ([@B21]; [@B199]; [@B122]; [@B337]), and anxiety ([@B12]).

Unfortunately, the results of postmortem studies on AD patients did not throw much light onto GABA~B~Rs role(s) in AD and this for good reasons\--one being the wide-ranging variability of the patients' terminal lifetime. Different alterations of biological parameters\--such as expression of RNA, proteins, and enzymes\--can be induced by co-morbidities, medications, aging, and leading death causes and are all directly linked to the duration and severity of the full-blown or symptomatic AD phase ([@B134]). Therefore, it is not surprising that divergent findings abound concerning GABA~B~Rs' possible role(s) in AD. Thus, recent postmortem studies of human brains and of *tg* AD-model animals reported that GABAergic neurons and GABA~B~Rs were unaffected by AD neuropathology ([@B202]). Conversely, earlier studies had conveyed the opinion that GABA~B~Rs signaling undergoes profound changes in AD ([@B310]). Significantly lowered GABA levels were detected in the temporal cortex of AD patients ([@B139]) and in cerebrospinal fluid (CSF) samples from both AD patients and the cognitively normal elderly ([@B138]). Conversely, raised GABA levels turned up in the hippocampus and CSF samples of AD patients and were ascribed to the impairment of synaptic plasticity ([@B169]). These studies also noted that the reactive astrocytes surrounding Aβs senile plaques overproduced GABA *via* monoamine oxidase-B (MAO-B) activity and abnormally released it through the bestrophin-1 channels. Under physiological conditions, bestrophin-1 channels are mostly localized at the microdomains of hippocampal astrocytes nearby glutamatergic synapses and mediate glutamate release. A switch from the glutamate-releasing normal astrocyte to the reactive astrocyte releasing GABA *via* bestrophin-1 channels is a common phenomenon occurring in various pathological conditions coupled with astrogliosis, such as traumatic brain injury, neuroinflammation, neurodegeneration, and hypoxic and ischemic insults. In AD, bestrophin-1 channels are redistributed to the soma and the processes of hippocampal reactive GABA-containing astrocytes. Bestrophin-1 channels-mediated GABA release from reactive astrocytes hinders synaptic plasticity and transmission and spatial memory by reducing dentate granule cell excitability ([@B246]). It was claimed that suppressing GABA overproduction by monoamine oxidase-B (MAO-B) or GABA overrelease through bestrophin 1 channels from the dentate gyrus reactive astrocytes fully restored learning and memory in AD-model mice ([@B169]). However, the long-term administration of selegiline, an irreversible MAO-B inhibitor, did not improve AD neuropathology in a clinical trial ([@B252]). To explain this unforeseen upshot, the authors suggested that multiple factors, like age, sex, and differences in brain regions could impact on the GABA release from astrocytes and neurons and should not be ignored when planning therapeutic drug attempts. Indeed, different brain regions of Tg2576 (human APP695 plus the Swedish double mutation K670N, M671L) AD-model mice released dissimilar amounts of GABA in relation to their actual age and sex. Cortical GABA levels were higher in older than 6 months female than male mice; however, at a more advanced age, this difference vanished in the parietal cortex but became more pronounced in the prefrontal cortex. Moreover, at 12--18 months of age, hippocampal levels of GABA were lower in female than in male mice. Altogether, these data revealed that with advancing age the functional disruption of GABA signaling turns out to be more intense in AD-model female mice ([@B155]). Conversely, under or up to 9 months of age, hippocampal GABA levels were higher in female than in male mice, likely because the former enjoyed the protective activity of estrogens ([@B286]). By extrapolating these data from animals to humans one can infer that a single therapeutic strategy addressing GABA~B~Rs modulation might not be so easily feasible in AD. In fact, any drug inhibiting the GABA~B~Rs residing in one brain region might exacerbate the dysregulation of GABAergic signaling in other brain areas.

Hence, the role(s) of GABA/GABA~B~Rs signaling in the pathogenesis of AD has(ve) hitherto remained unclear if not confusing ([@B134]). However, the recent studies we mention just below performed on wild-type and AD-model animals have thrown some more light on the contribution of GABAergic remodeling to the pathogenesis of both early and late stages of AD.

First, we recall here that the ε4 allele of apolipoprotein E (APOE) is the main known genetic risk factor for LOAD/SAD. Notably, in the brains of aged APOEε4 mice, an attenuation of GABAergic inhibitory inputs on associated excitatory neurons drives a specific neuronal hyperactivity phenotype. Hence, an APOEε4-driven hippocampal neuronal excitatory hyperactivity might be among the causative factors underlying the increased risk of AD among APOEε4 carriers ([@B242]). In addition, several AD-mouse models exhibit an early and marked neuronal hyperactivity in the hippocampus ([@B40]; [@B41]). Moreover, functional magnetic resonance imaging (fMRI) studies have revealed that humans with mild cognitive impairment (MCI), as well as presymptomatic carriers of EOFAD mutations show enhanced neuronal activity in the same brain region, the hippocampus ([@B271]; [@B141]). Therefore, when the increase in brain activity takes place early in the pathogenetic process it may be rightly considered a driving factor in AD development.

Second, according to a recent report, Aβs, AD's main drivers, are intensely degraded by endothelin-converting enzyme-2 (ECE-2) and neprilysin (NEP) in the somatostatinergic and parvalbuminergic synapses of GABAergic interneurons residing in the neocortex and hippocampus. These observations support the view that under physiological conditions Aβs may partake in the regulation of interneurons' inhibitory signaling in AD-relevant brain areas ([@B249]). However, it must be stressed here that a reduction of Aβs catabolism at the synapses of these two distinct populations of GABAergic neurons is not the unique GPCRs-mediated mechanism favoring Aβs accumulation in AD brains.

Third, the exciting results of very recent studies have revealed that GABA~B~R1a receptors bind three novel orthosteric agonists besides GABA, i.e. soluble (s)APP-α, sAPP-β, and sAPP-η proteins. The α-, β-, and η-secretases, respectively, shed them from the extracellular domain of APP into the brain environment. Next, each of these peptides can bind GABA~B~R1a receptors and block the release of neurotransmitters from hippocampal presynaptic excitatory axonal terminals thus silencing synaptic transmission. Most interesting, a 17-mer peptide of the ExD flexible portion of sAPP-α, which binds the extracellular Sushi1 domain of the GABA~B~R1a could replicate the squelching effect on neurotransmission brought about by the whole sAPP-α molecule. These results explain, at least in part, the synaptic dysfunction affecting some APP-overexpressing AD-model animals. Moreover, they suggest that this 17-mer peptide could therapeutically counteract the excitatory hyperactivity of neuronal synaptic function brought about by Aβs ([@B277]; [@B312]).

mGLURs AND AD {#s4}
=============

The seven-transmembrane-spanning mGluRs physiologically control synaptic transmission and neuronal excitability in the CNS and influence behavioral output processes. These receptors are assigned to three groups according to their G-protein coupling and signal transduction pathways. Group I encompasses mGluR1 and mGluR5; group II includes mGluR2 and mGluR3; and group III embraces mGluR4, mGluR6, mGluR7, and mGluR8. In general, group I receptors are coupled to the phospholipase (PL)C/InsP~3~/Ca^2+^ release cascade, whereas groups II and III receptors are linked up to the adenylyl cyclase/cyclic AMP/PKA release cascade ([@B240]). Initial studies performed with agonists (or antagonists), which bind the intragroup-shared extracellular orthosteric sites, indicated that activation of group II or group III mGluRs brought about neuroprotection, whereas activation of group I mGluRs elicited either neuroprotection or neurotoxicity according to experimental models and conditions employed ([@B238]; [@B38]). More recent studies using PAMs or NAMs, which are receptor subtype-specific, brought to light a somewhat different picture (see for references: [@B136]). Indeed, the allosteric modulation of mGluRs is a major area of interest for Basic and Clinical Pharmacology ([@B307]). In the CNS, mGluRs are involved in the regulation of glutamate uptake, cell proliferation, neurotrophic support, and proinflammatory responses. Accordingly, the potential therapeutic spectrum of mGluRs allosteric modulators embraces AD, and also covers PD, stress, anxiety, autism, depression, and schizophrenia ([@B307]).

Group I mGluRs (-1 and -5) {#s4_1}
--------------------------

Group I mGluR1 and mGluR5 are expressed at postsynaptic membranes, couple to Gαq, and positively modulate neuronal excitability through the interaction with scaffolding proteins such as Homer or Shank. The consequent activation of phospholipase C leads to an increase in \[Ca^2+^\]~i~. Activation of group I mGluRs may set off a multiplicity of neurons' and astrocytes' signaling pathways variously modulating synaptic plasticity and, likely, synaptic protein synthesis ([@B91]). These transduction mechanisms form a highly complex network including polyphosphoinositide hydrolysis, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), phospholipase D, phospholipase A2, phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), and the endocannabinoid 2-arachidonoylglicerol synthesis. Activation of ERK and mTOR by group I mGluRs is especially linked to *de novo* protein synthesis in neurons, a process that underlies long-term changes in activity-dependent synaptic plasticity. Group I mGluRs also enhance postsynaptic excitability thus exacerbating neuronal damage ([@B237]). It is also noteworthy to recall here that in preclinical studies *antagonists* of mGluR1 and mGluR5 exhibited anxiolytic-like properties just as did *agonists* of group II/III mGluRs ([@B306]).

By interacting with NMDARs, mGluR1 and mGluR5 regulate neuronal developmental plasticity. The interaction between group I mGluRs and NMDARs is reciprocal ([@B2]). Moreover, the expression of these receptors is developmentally regulated ([@B236]; [@B292]; [@B220]; [@B281]; [@B52]). Group I mGluRs are cross-linked with NMDARs through a chain of anchoring proteins ([@B319]), and their activation amplifies NMDA currents ([@B6]; [@B11]; [@B265]; [@B300]; [@B148]; [@B185]). In addition, activation of mGluR1 accelerates NMDARs trafficking ([@B190]). The NMDA component of long-term potentiation (LTP) is abolished in mice lacking mGluR5 ([@B167]). In cultured neurons and developing brains the interaction between mGluR5 and NMDAR is amplified by EphrinB2 ([@B45]), a ligand for EphB receptor tyrosine kinases playing a role in activity-dependent synaptic plasticity in the CNS ([@B302]).

In the developing brain, mGluR5 contributes to the functional maturation of astrocytes since mGluR5 ablation leads to serious deficits in arborization of astroglial processes and in the expression of glutamate transporters ([@B221]; [@B325]).

To date, the roles of group I mGluRs in the pathogenesis of AD are poorly understood and the object of controversy.

*In vitro* cultured fetal (E15) Sprague--Dawley rat neurons expressed mGluR1 whereas neonatal astrocytes did not. These findings limited to neurons the investigation of an alleged neuroprotective effect of the mGluR1/R5 *agonist*, 3,5-dihydroxyphenylglycine (DHPG), against Aβ neurotoxicity, which was instead suppressed by the mGluR1 *antagonist* JNJ 16259685 (3,4-dihydro-2H-pyrano(2,3-b)quinolin-7-yl)-(cis-4-methoxy-cyclohexyl)-methanone). Interestingly, estrogen-α receptors (E-αRs) could activate the same neuroprotection against Aβ toxicity and cell survival pathways as mGluR1 did. Indeed, E-αRs and mGluR1 were colocalized in cultured cortical neurons and were interdependent in activating the PI3K/Akt pathway that favors cell survival in pure neuronal cultures ([@B305]).

As regards mGluR5s, they are expressed by both astrocytes and neurons in all the CNS areas, signal through Gq protein ([@B324]), and partake in synaptic plasticity, assembly of neuronal circuitry, and neuronal viability ([@B14]; [@B268]).

Data gained from both *in vitro* and animal models suggest that the synaptic dysfunction of mGluR5s might favor the development of AD ([@B187]). mGluR5s are overexpressed by astrocytes as a reactive response induced by stimulation with growth factors (i.e. FGF, EGF, and TGF-β1) or by exposure to soluble Aβ oligomers (Aβ-os) *in vitro* ([@B53]; [@B137]; [@B204]). Aβ-os exposure also raises the expression of type I InsP3Rs, which are placed downstream from mGluR5, and strengthens Ca^2+^ responses mediated through the mGluR5/InsP~3~R cascade in hippocampal astrocytes ([@B137]). Notably, astrocytes surrounding Aβ senile plaques overexpressed mGluR5, which was associated with Ca^2+^ signaling dysregulation and abnormal ATP release in APP~swe~/PS1 transgenic AD-model mice ([@B299]). Reportedly, Aβ-os exposure caused an excessive clustering and widely reduced diffusion of Aβ-os/mGluR5 complexes on the plasma membrane of *in vitro* rat embryo astrocytes. These effects were coupled with an augmented Ca^2+^ influx altogether damaging synapses ([@B274]; [@B299]). Activation of mGluR5s by the allosteric agonist DHPG increased ATP release from Aβ-os-exposed astrocytes, which delayed mGluR5 diffusion in cultures of astrocytes plus/minus neurons *in vitro* ([@B274])---an effect mGluR5's selective antagonist MPEP counteracted thus preventing Aβ-os/mGluR5-driven synaptotoxicity ([@B299]).

Interestingly, proinflammatory cytokines like interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) downregulated the expression of mGluR5 while upregulating that of mGluR3 in cortical astrocytes isolated from the hSOD1(G93A) rat model of amyotrophic lateral sclerosis (entailing like AD an intense neuroinflammation) and cultured *in vitro*. These findings suggested the existence of a protective antiexcitotoxic adaptive mechanism ([@B23]). In fact, the mGluR5 selective antagonist MPEP hampered the astrocytes' secretion of two proinflammatory cytokines, IL-6 and IL-8 ([@B298]). Therefore, the activation of astrocytes' mGluR5 advances the release of proinflammatory cytokines, which then downregulate mGluR5 expression. This indicates that under physiological conditions a reciprocal feed-back mechanism controls the expression levels of mGluR5 in astrocytes and in microglia too ([@B23]). This mechanism might be offset by the Aβ-os-forced overexpression of mGluR5 in AD, thus potentiating the release of toxic amounts of proinflammatory cytokines and glutamate. Next, the latter increases the production/release of p-Tau-os and of NO and the activity of apoptotic caspase-3 ([@B311]; [@B196]).

Another noteworthy study showed that the activation of mGluR5 stimulated the α-secretase-mediated extracellular shedding of neurotrophic and neuroprotective sAPP-α ([@B304]), also an agonist of GABA~B~R1a receptors ([@B277]). But mGluR5 forms complexes with the Homer proteins that interact with and activate NMDARs ([@B319]; [@B11]; [@B9]; [@B223]). Aβ~1-42~-os can bind mGluR5s and enhance their clustering together, causing mGluR5 signaling overactivation, intracellular Ca^2+^ accumulation, impaired calcium homeostasis, and synaptic disruptions ([@B274]; [@B346]). In greater detail, mGluR5s act as coreceptors for Aβ-os bound to prion protein (PrP^c^). Next PrP^c^ activates the mGluR5, which elicits the loss of synapses through *Fyn* tyrosine kinase activation and eukaryotic elongation factor 2 (eEF2) phosphorylation ([@B320]). *Fyn* phosphorylates NR2A and NR2B subunits of NMDA receptors thus altering the receptors' intracellular trafficking that is essential for synaptic plasticity. Moreover, interactions between *Fyn* tyrosine kinase and Tau proteins play a role in regulating the synapse function and the postsynaptic toxic signaling pathways driven by Aβ-type excitotoxicity, causing the loss of dendritic spines. Notably, Aβ-os exposure also induces the eEF2 phosphorylation by eEF2 kinase that is known to associate with mGluR5. Aβ-os-induced impairment of LTP is dependent on eEF2 phosphorylation that is increased in brains from both *tg* AD-model mice and AD patient autopsies ([@B243]).

Altogether these data support the view that mGluR5 activation by specific PAMs facilitates excitotoxic mechanisms causing the death of neurons ([@B254]), whereas mGluR5-specific NAMs act neuroprotectively in AD-model animals ([@B39]). Administering MPEP, a mGluR5 selective antagonist, prevents this synaptic loss in *tg* AD-model mice ([@B272]; [@B156]; [@B187]). In addition, deletion of mGluR5 prevents memory loss in AD-model mice ([@B144]). But to gain these benefits there is a price to pay, which is the negative impact of mGluR5 selective antagonists on activity-dependent synaptic plasticity mechanisms in brain regions that are not affected by AD ([@B39]). Of course, the translatability of these interesting results to human AD patients remains a topic worth exploring.

Group II mGluRs (-2 and -3) {#s4_2}
---------------------------

Group II mGluR2 and mGluR3 are mostly localized presynaptically. Depending on the nature of the ligand, mGluR2s signal *via* Gi/o or Gq11 proteins ([@B128]; [@B116]) and negatively modulate neuronal excitability ([@B77]). Thus, activation of group II mGluRs is endowed with potential neuroprotective properties as it may curtail glutamatergic signaling and mitigate neuronal hyperexcitability ([@B237]). Stimulation of group II mGluRs inhibits adenylyl cyclase (AC), activates K^+^ channels, and blocks presynaptic voltage-gated calcium channels, thus hindering intracellular Ca²^+^ fluxes and synaptic neurotransmitters release ([@B20]; [@B240]). Groups II mGluRs also team with the MAPK and PI3K pathways to confer neuroprotection ([@B94]). As mentioned also below, neuroprotection is mediated by transforming growth factor-β1 (TGF-β1) released through astrocytes' mGluR3 signaling. TGF-β1 binds and activates its membrane receptors coupled with serine/threonine kinase activity thereby inducing the *Smad* signaling cascade. It also synergistically operates with other neurotrophins such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial-derived neurotrophic factor (GDNF) ([@B48]). In the rodents' thalamus, the selective activation of mGluR2 modulates the inhibition at synapse level of sensory neurons functionally linked to information processing, attention, and cognition ([@B80]). Conversely, the selective activation of mGluR2 increases the incidence of neuronal deaths *in vitro* ([@B82]; [@B48]). Accordingly, a mGluR2-specific NAM hindered the death of ischemia-sensitive neurons in the hippocampal CA1 area, whereas a mGluR2-specific PAM promoted the death both of ischemia-sensitive CA1 neurons and of ischemia-resistant CA3 neurons ([@B222]). Recent investigations have revealed the formation of intragroup and intergroup heterodimers between different mGluRs ([@B99]; [@B283]; [@B172]). New allosteric modulators capable of differentiating homodimers from heterodimers have disclosed the assembly of mGluR2/mGluR4 heterodimers in corticostriatal fibers ([@B344]).

The mGluR3, whose activation inhibits AC activity and hence cyclic AMP production, is the most abundant astroglial receptor along all the lifetime ([@B309]). Mounting evidence indicates that mGluR3 upkeeps synaptic homeostasis, including synaptic plasticity and synaptogenesis (see for references: [@B101]). In addition, activated mGluR3 plays major neuroprotective roles in AD and other neuropathologic conditions. Once added to pure cultures of newborn rat astrocytes, the orthosteric agonists LY379268 or LY354740 specifically activated mGluR3 (rodent astrocytes do not express mGluR2), promoting the production and release of TGF-β and of GDNF (see also above and [@B49]). The same agonists increased the expression of α-secretase, whose activity is essential for APP's physiological *NAP*. The upshot is an amplified extracellular shedding of the neurotrophic and neuroprotective and GABA~B~R1a agonist sAPP-α ([**Figure 1**](#f1){ref-type="fig"}) ([@B35]; [@B36]; [@B82]; [@B17]; [@B95]; [@B18]; [@B277]). Moreover, an indirect role for mGluR3 in AD is denoted by the progressive decrease with aging in mGluR2 and mGluR3 expression and, consequently, in their antiamyloidogenic action in hippocampal astrocytes from PDAPP-J20 AD-model mice ([@B102]). In subsequent studies, the same authors showed that the LY379268-elicited activation of astrocytes' and neurons' mGluR3 suppressed or mitigated the Aβ-driven neurotoxicity and death of both neurons and astrocytes. In both cell types, agonist-activated mGluR3 increased the shedding of neuroprotective sAPP-α and the expression of BDNF. In addition, LY379268-activated mGluR3s induced astroglia- and microglia-mediated phagocytosis and removal of Aβs from the extracellular environment. Finally, mGluR3 orthosteric agonists LY379268 or LY404039 suppressed the nitric oxide (NO)-induced death of cultured rat astrocytes *via* the inhibition of AC, which reduced intracellular cAMP levels, the activation of Akt, and the formation of antiapoptotic p65 and c-Rel complexes of the NF-κB family ([@B100]; [@B103]).

Conversely, [@B49] showed that mGluR2 and mGluR3 enhanced neurotoxicity in pure cultures of rat brain neurons challenged with Aβ~1--42~ or with its neurotoxic fragment Aβ~25--35~. However, if the neurons were cocultured with the astrocytes, the activation of mGluR2 and mGluR3 brought about neuroprotective effects through the release of TGF-β~1~ from the astrocytes. TGF-β~1~ is a well-known agent endowed with neuroprotective and anti-inflammatory activities (see also above) in experimental AD-models ([@B60]) as it also stimulates microglia to scavenge Aβs ([@B317]).

Group III mGluRs (-4, -6, -7, and -8) {#s4_3}
-------------------------------------

Group III mGluRs (-4, -6, -7, and -8) are mainly localized presynaptically, couple to Gαi/o, and negatively modulate neuronal excitability ([@B77]). They are likely to act as autoreceptors on glutamatergic synaptic terminals and as heteroceptors on GABAergic and other neurotransmitter terminals ([@B51]; [@B110]). Group III mGluRs stimulation results in AC inhibition, K^+^ channels activation, and block of presynaptic voltage-gated calcium channels, thus decreasing Ca²^+^ flow into cells and neurotransmitters release from synapses ([@B20]; [@B239]). Therefore, their activation elicits potential neuroprotective effects that dampen glutamatergic signaling and inhibit neurotransmitters release thereby mitigating neuronal excitability ([@B237]). As a particularity, activated mGluR7 stimulates protein kinase C (PKC) or phospholipase C resulting in the inhibition of neuronal calcium channels ([@B258]; [@B257]). Brain expression of mGluR4, -7, and -8 is proper of cortical and hippocampal neurons and of synapses located in the basal nuclei (striatum, pallidum), subthalamic nucleus, and substantia nigra (both pars compacta and pars reticularis) ([@B34]; [@B108]; [@B154]). Instead, mGluR6 expression is exclusive of the retina ([@B226]). The main subcellular location of mGluR7 is at the central area of presynaptic terminals just where the membrane coalesces with synaptic vesicles: this suggests its involvement in the modulation of neurotransmitter release. Conversely, mGluR4 and mGluR8 are placed at the periphery of presynaptic terminals ([@B291]; [@B293]; [@B251]). Group III mGluRs also cooperate with MAPK and PI3K signaling pathways to impart neuroprotection ([@B160]). Recently, these receptors have become the focus of therapeutic attempts because they (i) can modulate defective neurotransmission yielding symptomatic improvements through the neuroprotective hindering of multiple neurodegenerative mechanisms and (ii) have more favorable safety and tolerability profiles ([@B154]). Activation of group III mGluRs by glutamate and/or other agonists is neuroprotective as it inhibits glutamate release from neurons' presynaptic terminals and from microglia, thus mitigating excitotoxicity; concurrently, astrocytes intensify the uptake of glutamate and microglia increase neurotrophic factors synthesis (see [@B333] for an in-depth review on this topic).

Rather few studies exist about the effects on a neurodegenerative disease like AD exerted by group III mGluRs activation *via* broad spectrum agonists and PAMs or inactivation *via* NAMs. [@B79] reported that broad-spectrum group III mGluRs agonists L-serine-O-phosphate (L-SOP) and l-2-amino-4-phosphono-butanoate (L-AP4) could lessen the apoptotic death rate of neurons exposed to Aβs. The authors suggested that such agonists would exert neuroprotective effects in AD. Similarly, group III agonist RS-PPG, which activates preferentially mGluR8 and likely also mGluR4, exerted neuroprotective actions on neurons exposed to harmful hypoxic or hypoglycemic conditions ([@B37]; [@B288]). Notably, acute hypoxia can induce neurons to overproduce lethal amounts of Aβs *via* a mechanism. involving another family C GPCR, the CaSR ([@B180]; [@B13]). Besides, PHCCC, a specific mGluR4 PAM, and also a partial antagonist of group I mGluRs, protected cultured cortical mouse neurons against the Aβs-elicited cytotoxicity and NMDAR excitotoxicity ([@B208]).

But what about the astrocytes? Under basal conditions, rodent (rat and mouse) astrocytes in primary cultures express mGluR4, but neither mGluR7 nor mGluR8 ([@B263]; [@B164]). However, mGluR8 is expressed by reactive astrocytes adjacent to chronic inflammatory lesions ([@B127]). [@B24] provided evidence that broad spectrum orthosteric agonists activating group III mGluRs, like L-AP4, 4-phosphonophenylglycine (4-PPG), or L-SOP hindered the expression and secretion of the proinflammatory chemokine RANTES in astrocyte cultures. These beneficial effects of the mGluR4 broad spectrum agonists were counteracted by pretreating the astrocytes cultures with the selective group III mGluRs NAM (R,S)-α-methyl-serine-O-phosphate or with pertussis toxin. Altogether, these findings suggest that such agonists might mitigate neuroinflammation in conditions like AD, multiple sclerosis, and experimental allergic encephalomyelitis.

Extracellular glutamate homeostasis, which is essential for physiological glutamatergic neurotransmission and excitotoxicity prevention, depends on the activity of astrocytes' transporters like GLT-1 and GLAST ([@B5]). Neuroinflammatory conditions associated with a neurodegenerative disease like AD or experimental treatments (e.g. with LPS, MPTP, etc.) reduce astrocytes' GLT-1- and GLAST-mediated glutamate uptake due to a fall in endogenous antioxidant glutathione (GSH) activity. Broad spectrum group III mGluRs agonists rescue GSH normal levels and restore astrocytes' GLT-1- and GLAST-mediated glutamate uptake alleviating neuronal excitotoxicity ([@B340]; [@B348]; [@B113]). Thus, activation of astrocytes' group III mGluR3 and mGluR5 and also of group II mGluRs by broad spectrum agonists increases GLT-1- and GLAST protein expression and glutamate uptake activity as the signaling of both groups likely involves Gi/o, MAPKs, and PI3K pathways ([@B8]; [@B19]; [@B333]). The activation of group III mGluRs by wide spectrum agonists also curtails the release of proinflammatory cytokines from activated microglia ([@B73]). Wide spectrum group III mGluRs agonists also hinder proinflammatory cytokines release, RANTES included, from the astrocytes exposed to neurotoxic agents ([@B216]; [@B24]), thereby helping mitigate neuroinflammation and reduce neuronal demise. Therefore, one might surmise that the effects of these agonists on astrocytes and microglia would likely impact on the course of AD and perhaps also of other neurodegenerative diseases.

Calcium Sensing Receptor {#s5}
========================

The CaSR is a (poly)cationic receptor, as its evolutionary history shows ([@B275]). This is why CaSR's preferred yet not unique orthosteric agonist is Ca^2+^. A CR region, necessary for receptor activation ([@B157]; [@B151]) connects CaSR's huge (∼612 amino acids) ECD, the bilobed (LB1 and LB2) VFT to the 7TM domain whose seven transmembrane α-helices (TM1--TM7) are joined by three extracellular and three intracellular loops. Two domains of the CASR's intracellular C-terminal tail are necessary for CaSR expression at the cell surface and its composite signaling functions *via* G-proteins (see below). The VFT contains the binding pockets for the orthosteric (type I) agonists ([@B151]), which besides extracellular Ca^2+^ ([@B153]), include various divalent and trivalent cations, polyamines, aminoglycoside antibiotics, and cationic polypeptides ([@B301]; [@B289]; [@B207]; [@B345]). The CaSRs of human cortical astrocytes also specifically bind Aβs, likely at the VFTs ([@B87]; [@B88], [@B90]). Moreover, X-ray crystallography studies ([@B126]) have revealed that in the resting state the 3D structure of CaSR's ECD exhibits an open conformation kept up by PO~4~ ^3−^ anions. Independently of the presence or absence of Ca^2+^ ions, CaSR activation occurs when an L-α-amino acid closes the VFT groove, triggering the formation of a new homodimer interface between the membrane-proximal LB2 and the CR domains. Ca^2+^ ions stabilize the active state to fully activate the receptor. Indeed, CaSR's ECD is endowed with four Ca^2+^-binding sites, of which the Ca^2+^ ion at site \#4 stabilizes, upon orthosteric agonist binding, the CaSR homodimer's active conformation ([@B126]). Importantly, orthosteric agonists also induce the dissociation of inhibitory PO~4~ ^3−^ anions from the arginine residues acting as their relatively weak binding sites. Thus, the CaSR-inactivating action of bound PO~4~ ^3−^ anions is overturned ([@B270]; [@B61]; [@B126]). As the other GPCRs do, CaSR swings between conformation-varying active and inactive states ([@B285]). The changes in conformation due to activation include a rearrangement of the 7TM and ICD domains. The CaSR's 7TM helical domains can modulate signal transduction. The 7TM's intracellular loops 2 and 3 are crucially involved in the activation of downstream effectors ([@B130]). Besides, various CaSR's 7TM sites bind allosteric (type II) ligands. The latter include both the aromatic L-α-amino acids and the highly selective *allosteric agonists* or *PAMs*, short-termed *calcimimetics*, and *allosteric antagonists* or *NAMs*, short-termed *calcilytics* ([@B230]). As will be discussed later, these pharmacological agents offer exciting perspectives in the field of clinical therapeutics. In response to orthosteric ligand binding, the CaSR's ICD tails interact with G~s~ or G~q/11~ or G~12/13~, or G~i/o~, proteins ([@B55]; [@B153]; [@B75]), and with β-arrestin 1/2 ([@B316]). Such interactions turn on several signaling pathways ([@B289]; [@B207]), which underlie the receptor's complex actions and comprise: (i) second messenger-producing enzymes (e.g., AC); (ii) phospholipases A2, C, and D; (iii) protein kinases (e.g. PKCs, MAPKs, AKT); (iv) Ca^2+^ influx *via* TRPC6-encoded receptor-operated channels; and (v) transcription factors (reviewed in [@B345]). Moreover, the intracellular adaptor-related protein complex (AP2) binds the CaSR's ICD promoting the receptor's clathrin-mediated endocytosis ([@B235]). Finally, CaSR's ICD ubiquitylation and phosphorylation modulate the receptor's recycling, degradation, and desensitization ([@B349]; [@B31]).

In general, the CaSR preserves systemic Ca^2+^ homeostasis by promptly sensing any changes in the extracellular calcium concentration \[Ca^2+^\]~e~ and, accordingly, by modulating the amounts of parathyroid hormone (PTH) released from parathyroid glands as well as the reabsorption of Ca^2+^ from kidneys and its deposition in bones ([@B153]). Dysfunctions of the CaSR severely alter systemic Ca^2+^ homeostasis ([@B33]; [@B150]). Gain-of-function CaSR mutations result in autosomal dominant hypocalcemia, whereas loss-of-function CaSR mutations cause severe neonatal primary hyperparathyroidism ([@B150]; [@B328]; [@B145]).

But, what about the CaSR in the brain? All types of brain neural and cerebrovascular cells express the CaSR, with particular intensely in the hippocampus, an AD-relevant area ([@B59]; [@B341]; [@B241]). [@B85] showed that untransformed astrocytes isolated from the adult human temporal cortex and cultured *in vitro* express functional CaSRs, less intensely when proliferating but more strongly when mitotically quiescent. Notably, changes in the growth medium \[Ca^2+^\]~e~ did not impact on CaSR expression levels by adult human astrocytes. But preservation of systemic Ca^2+^ homeostasis is not the CaSR's main task in the brain. In fact, fluctuations in \[Ca^2+^\]~e~ physiologically modulate, *via* corresponding adaptations of CaSR signaling, a variety of neural cells activities like CaSR's L-amino acid sensing ([@B74]), K^+^ fluxes ([@B58]), proliferation, differentiation, migration of both neurons and oligodendrocytes during growth, and synaptic plasticity and neurotransmission during postnatal life ([@B15]; [@B276]; [@B287]; [@B180]; [@B241]; [@B313]).

Remarkably, CNS diseases, such as AD and ischemia/hypoxia/stroke, change the CaSR's expression levels and hence alter the cellular processes CaSR signaling regulates ([@B7]; [@B87]; [@B88]; [@B13]; [@B90]). The first hint that the CaSR might play a role in AD pathogenesis stemmed from the observation that Aβs-elicited peaks of cytosolic \[Ca^2+^\]~i~ had a killing effect on hippocampal neurons ([@B32]). A second clue was the opening of Ca^2+^-permeable nonselective cation channels (NSCCs) by fibrillar Aβ~1--40~ or Aβ~25--35~ in hippocampal neurons of wild type (WT) *CaSR* ^+/+^ rats; notably, this effect could not be replicated in *CaSR* ^−/−^ rats. The authors speculated that Aβs might bind the CaSR because they have, just like polyamines, orderly spaced arrays of positive charges ([@B343]).

In this regard, the specific formation of plasma membrane Aβs•CaSR complexes and their subsequent endocytosis in cultured cortical untransformed adult human astrocytes could be proven by using the *in situ* proximity ligation assay (isPLA), which reveals the specific formation of stable complexes between two molecules placed within a 30 nm range ([@B87]; [@B88]; [@B90]). The latter results implied that since all types of human neural and cerebrovascular cells express the CaSR, they are vulnerable to the neurotoxic effects driven by pathological Aβ•CaSR signaling ([@B63]). However, it remains to be ascertained whether at the level of CaSR•GABA~B~R1 heterodimers of human cortical astrocytes and neurons Aβs•GABA~B~R1 complexes also form and what their functional roles would be under both physiological and pathological conditions: topics worth investigating further.

Moreover, a genetic analysis study on cohorts of 435 healthy controls and 692 SAD patients showed that an intron 4 polymorphic dinucleotide repeat marker of the *CASR* gene associated with an AD susceptibility, while three nonsynonymous SNPs of exon 7 were linked with an AD propensity only in non-*APOEε4* allele carriers. Hence, variations in the *CASR* gene sequence may impact on SAD susceptibility especially in subjects having no *APOEε4* allele ([@B76]).

The *CASR* gene P1 and P2 promoters regulate its transcription by binding several transcription factors, including SP1, SP3, STAT1, STAT3, CREB, and NFκB, which concurrently control the expression of other AD-related genes (see for details and references: [@B63]). Therefore, the transcription factors regulation of CaSR expression is tightly linked to the pathophysiology of AD.

It is well known that Aβ~42~-os simultaneously bind to several other CNS cells surface receptors besides the CaSR (see for details and references: [@B63]). Therefore, Aβ~42~-os•CaSR signaling triggers a throng of cellular responses sosme authors include in the so called "*calcium dyshomeostasis*", such as toxic ROS overrelease from mitochondria, and intracellular Ca^2+^ surges *via* NMDARs' activation driving further mitochondrial ROS releases ([@B171]; [@B165]).

However, it must be stressed here that the pathological Aβ~42~-os•CaSR signaling performs much more AD-specific upstream feats than those just mentioned. In fact, it drives the overproduction and overrelease of Aβ~42~-os and p-Tau-os, the two main AD culprits, from human cortical neurons and astrocytes. Moreover, it also induces the production and release of surpluses of other neurotoxic agents, such as NO and VEGF-A, and likely others more, from the adult human cortical astrocytes. Additionally, the pathological Aβ~42~-os•CaSR signaling profoundly suppresses sAPP-α extracellular shedding from human astrocytes and neurons ([@B63]; [@B64]; [@B65]). These Aβ-os-elicited noxious effects associate with concurrent upsurges in the expression of APP, BACE1, and CaSR proteins. Remarkably, the crucial upshot of all the mentioned effects of Aβ~42~-os•CaSR signaling is the death of human cortical neurons both *in vitro* ([@B7]) and in the *in vivo* brain. In the latter, the progressive disconnections of neural circuits---a cause of advancing cognitive decline---and a chronic diffuse reactive neuroinflammation eventually lead to full blown or symptomatic AD ([@B83]; [@B175]; [@B215]).

Moreover, a study using *3xTg* AD-model mice showed that the amount of brain CaSR immunoreactivity progressively increased with age, particularly in areas where Aβ~42~ fibrils accumulate most, such as the hippocampi. Thus, local fibrillar Aβ~42~ buildup and CaSR expression raise in parallel in both Aβ-exposed human cortical neurons and astrocytes cultured *in vitro* and in the hippocampi of *3xTg* AD-model mice ([@B7]; [@B63]; [@B123]). This soaring expression of neural cells' CaSRs associates with a declining expression of inhibitory GABA~B~R1as ([@B57]; [@B180]).

Whereas GABA~B~ and taste receptors obligatorily function as heterodimers ([@B170]; [@B228]), mGluRs and CaSR function both as disulfide-linked homodimers ([@B347]; [@B264]) and as CaSR/GABA~B~Rs, CaSR/mGlu1αR and CaSR/mGlu5R heterodimers ([@B120]). Ectopic overexpression and coimmunoprecipitation studies revealed that CaSR/GABA~B~R1a heterodimers do affect CaSR protein expression in opposing ways. The total and cell surface expression and signaling of the CaSRs were suppressed by coexpressing GABA~B~R1as, being instead increased (i) by co-expressing GABA~B~2Rs; (ii) by knocking out GABA~B~R1a in mouse brains; and (iii) by deleting GABA~B~R1a in cultured hippocampal neurons. The GABA~B~Rs and CaSRs form heterodimers as soon as they are synthesized, since these protein complexes are already detectable around the cells' nuclei and in the endoplasmic reticulum. In such early complexes GABA~B~Rs bind an immature form of the CaSR. Clearly, GABA~B~R1a and GABA~B~R2 subunits compete for the CASRs. The CaSR/GABA~B~R heterodimers appear to have altered pharmacological properties with respect to the prevailing CaSR homodimers. Results gained using (i) the GABA~B~Rs agonists baclofen and GABA, (ii) the GABA~B~R1a antagonist CGP-3548, and (iii) GABA~B~R1a expression knockdown in cultured mouse growth plate chondrocytes indicated that GABA~B~R1a can elicit both CaSR-independent and CaSR-mediated actions. However, divergent results gained from different experimental models suggested that an endogenous expression or a targeted overexpression of one or more of these receptors, coexisting differences in ligands and in their relative quantities and in downstream intracellular signaling pathways could elicit unlike upshots under various physiological and/or pathological conditions ([@B120]; [@B57]). During the initial phases of disease progression in AD-model animals, the decline of GABA~B~R1s' availability, which concurs with CaSR's overexpression, induced a *neuronal hyperactivity* in hippocampal and cerebrocortical circuits, whose upshot was functional impairment ([@B42]). The mechanism(s) underlying this loss of neuronal working capability remain(s) unclear: an overconsumption of O~2~ on the part of the hyperactive neurons might be a contributory factor. Nothing is so far known about the existence and pathophysiological roles of CaSR heterodimers in cortical human untransformed astrocytes and neurons. Therefore, to-date the impacts (if any) the CaSR/GABA~B~Rs and CaSR/mGluRs heterodimers might exert on human AD's course and on anti-AD therapeutic approaches remain to be assessed.

Notably, in cortical adult human astrocytes the pathological Aβ•CaSR signaling heavily affects the APP holoprotein metabolism significantly deflecting it from its physiological *NAP* ([**Figure 3**](#f3){ref-type="fig"}). APP's *NAP* typically obstructs the *de novo* production of Aβ~42~s/Aβ~42~-os since the α-secretases (mainly ADAM 10) cut the APP molecule just within the Aβ~42~ amino acid sequence ([@B186]) ([**Figures 1**](#f1){ref-type="fig"} and [**3**](#f3){ref-type="fig"}). Notably, APP's *NAP* prevails over APP's *AP* in untreated (control) cortical adult human astrocytes, which directly shed all the sAPP-α they produce into the environment while secreting only tiny amounts of monomeric Aβ~42~ ([@B65]). Hence, it has been posited that by constitutively releasing substantial amounts of sAPP-α, which is an agonist of GABA~B~R1as ([@B277]), human astrocytes could continually abate any noxious neuronal hyperexcitability. Under the same basal conditions, CaSR signaling is only modulated by extracellular cations levels, particularly by the \[Ca^2+^\]~e~. On the other hand, a dramatic change in this mechanism occurs when increased quantities of exogenous Aβs bind the human astrocytes' (and neurons') CaSRs and activate their pathological signaling that strongly promotes APP's *AP* over APP's *NAP* ([**Figure 3**](#f3){ref-type="fig"}). This leads to an excess production, accumulation, and secretion of neurotoxic Aβ~42~/Aβ~42~-os from the cortical astrocytes and from the neurons in which an alike APP's *AP* mechanism operates ([@B7]). Concurrently, the astrocytes' and neurons' intense extracellular shedding of sAPP-α is curtailed by ∼70%, while sAPP-α abnormally accumulates within the cells ([@B64]). On the basis of such results the authors posited that an ongoing Aβ•CaSR signaling that would spread in vicious cycles from teams to teams of "*master*" astrocytes' and "*client*" neurons could cause a substantial loss of the neurotrophic and neuroprotective effects otherwise brought about by extracellularly shed sAPP-α, including its agonistic action on GABA~B~R1as, thereby favoring a harmful neuronal hyperexcitability. In addition, the Aβ~42~/Aβ~42~-os-exposed human astrocytes and neurons could simultaneously release increasing amounts of neurotoxic Aβ~42~-os ([@B7]), p-Tau-os (within exosomes) ([@B64]), NO, VEGF-A ([@B85]; [@B62]; [@B87]; [@B88]; [@B63]). and likely other noxious agents. Therefore, it would not be surprising that under such dire circumstances cortical human neurons keep losing synapses and consequently die. Interestingly, in line with the just mentioned findings, CSF levels of sAPP-α significantly decrease in LOAD/SAD patients ([@B201], which indirectly confirms the substantial fall of its extracellular shedding from human astrocytes ([@B65]).

![The pathological effects of Aβ•CaSR signaling on the metabolic processing of amyloid precursor protein (APP) and Tau proteins in untransformed cortical human astrocytes and neurons and their complete suppression by highly selective calcium-sensing receptor (CaSR) negative allosteric modulators (NAMs) (or calcilytics). Under physiological conditions, the *NAP* of APP largely prevails in cortical human astrocytes and neurons. Conversely, the pathological Aβ•CaSR signaling hugely enhances the APP holoprotein's *AP* at the expense of *NAP* in both human cell types. This leads to a surplus synthesis, intracellular accumulation, and extracellular release of Aβ~42~-os. The latter spread extracellularly to bind and activate the signaling of the CaSRs of adjoining teams of astrocytes and neurons ([@B64]). Such self-sustaining vicious cycles amplify and propagate the pathological Aβ•CaSR signaling and its neurotoxic effects to wider and wider cortical areas. The Aβ•CaSR signaling also increases the activity of the glycogen synthase kinase-3β (GSK-3β), which strongly phosphorylates Tau proteins at amino acid sites typical of Alzheimer's disease (AD). The thus hyperphosphorylated Tau proteins also form oligomers (p-Tau-os) that are next released extracellularly within exosomes (not shown), thereby starting the tauopathy typical of AD. Other noxious effects of Aβ•CaSR signaling, such as increases in the synthesis and release of nitric oxide (NO) and vascular endothelial growth factor-A (VEGF-A), and other proinflammatory agents are not shown here for the sake of clarity. The crucial upshot of the harming effects of pathological Aβ•CaSR signaling is the progressive death of the cortical human neurons crucially involved in memories and cognition processing. In a most striking fashion, highly selective CaSR NAMs (calcilytics) suppress *all* the just mentioned neurotoxic effects brought about by pathological Aβ•CaSR signaling thus restoring the APP's *NAP*, Tau, NO, and VEGF-A to their physiological settings and consequently preserving the viability and function of human neurons notwithstanding the presence of Aβ peptides. Hence, NAMs could stop AD progression, safeguard the survival of the cortical human neurons, and preserve the memories, cognitive and coping capabilities of the patients. --- blocking effects; +++, stimulating effects.](fphar-10-01282-g003){#f3}

CaSR NAMs as Potential Anti-AD Therapeutics {#s5_1}
-------------------------------------------

As mentioned above, several PAMs and NAMs of the CaSR are available. L-α-amino acids with an aromatic ring and positively charged amino groups (NH^3+^) are naturally occurring CaSR PAMs ([@B194]). Synthetic phenylalkylamine CaSR PAMs ("*calcimimetics*"; e.g. AMG 416, Cinacalcet, and NPS R-568) having two-to-four aromatic rings and NH^3+^ groups have been synthesized. PAMs augment the CaSR's sensitivity to activation by \[Ca^2+^\]~e~ and hence lower the EC~50~ for \[Ca^2+^\]~e~. Notably, three CaSR PAMs, i.e. Evocalcet, Etelcalcitide, and Cinacalcet, have successfully reached the clinical use to mitigate primary and secondary hyperparathyroidism and tumor-elicited hypercalcemias ([@B234]).

CaSR NAMs are small amino-alcohol molecules like NPS 2143 ([@B229]), Calhex 231 ([@B178]), NPSP795 ([@B119]), or quinazolinones like ATF936 and AXT914 ([@B331]). CaSR NAMs right-shift the \[Ca^2+^\]~e~ response curve decreasing the CaSR sensitivity to \[Ca^2+^\]~e~ and thus increasing the EC~50~ for \[Ca^2+^\]~e~ ([@B112]; [@B158]). As previously anticipated, both PAMs and NAMs bind the 7TM domain of the CaSR. The CaSR binding pockets of NAMs and PAMs partially overlap but are not identical. NAMs bind between the TM3 and TM5 loops, whereas both PAMs and NAMs attach between the TM6 and TM7 loops ([@B260]; [@B261]; [@B218]). It has been shown that point mutated residues of the 7TM helices (i.e. Phe^668^, Phe^684^, Trp^818^, Phe^821^, Glu^837^, and Ile^841^) lessen the antagonism of CaSR NAM NPS 2143 ([@B260]; [@B261]; [@B218]). CaSR's allosteric agonism and antagonism are modulated *via* the involvement of distinct amino acids and mechanisms (see for further details [@B193]; [@B176]). The identification of synthetic allosteric modulators of the CaSR has prompted searches for their therapeutic applications in diseases in which the CaSR signaling is dysfunctional ([@B145]). However, hitherto the therapeutic potentials of both PAMs and NAMs of the CaSR have been only modestly exploited (Nemeth, 2013; [@B289]; [@B332]; [@B328]). Like other GPCRs, CaSRs exhibit the "*ligand-biased signaling*" feature, i.e. in a certain type of cell a signaling pathway may be steadily picked up over the others according to the specific ligand involved ([@B192]). Interestingly, NAMs and PAMs too can induce this biased signaling, which in future might allow to therapeutically target a speciﬁc cell type over others (see for details: [@B92]; [@B192]; [@B145]).

Let's zero in on an important NAMs' feature: they enhance parathyroid hormone (PTH) secretion from the parathyroid glands and increase blood calcium levels (calcemia) ([@B231]; [@B232]). Several phase II clinical trials were undertaken to assess CaSR NAMs potential therapeutic efficacy in women with postmenopausal osteoporosis based on the assumption that the released PTH would stimulate osteogenic processes. However, these trials failed because NAMs induced a several hour-lasting oversecretion of PTH that stimulated both osteogenic and osteolytic processes in the osteoporotic bones. These failures prompted to search for new CaSR NAMs inducing a lesser and shorter-lasting PTH release (Nemeth, 2013; [@B275]; [@B92]; [@B328]). The same failures also demoted CaSR NAMs from the drugs potentially beneficial in humans even because of the modest hypercalcemia (hyperparathyroidism) they induced. However, attempts were performed to treat hypoparathyroidism and autosomal dominant hypocalcemia (ADH) driven by gain-of-function CaSR mutations with CaSR NAMs (Nemeth, 2013; [@B330]; [@B200]; [@B253]; [@B234]). The use of CaSR NAMs was also considered in cases of breast and prostate carcinomas to prevent bone metastases, which are established through a CaSR-mediated signaling ([@B203]; [@B219]). Other potential therapeutic uses of CaSR NAMs have included asthma attacks ([@B342]); pulmonary artery idiopathic hypertension ([@B338]; [@B339]); stroke ([@B180]); and, last but not least, LOAD/SAD and EOFAD ([@B7]; [@B63]; [@B64]; [@B65]; [@B66]).

The use of CaSR NAMs as therapeutics in SAD/LOAD and EOFAD is supported by the results gained from preclinical AD models "in Petri dishes" made up by untransformed human cortical astrocytes and/or neurons. In fact, a 30-min administration of a CaSR NAM, be it NPS 2143 or NPS 89696, completely suppressed all the above-mentioned neurotoxic responses evoked by the pathological Aβ•CaSR signaling ([@B62]; [@B7]; [@B88]; [@B89]; [@B63]; [@B66]). Therefore, the authors posited that *in vivo* administered CaSR NAMs would (A) preserve the shedding of neurotrophic and neuroprotective and GABA~B~R1a agonist sAPP-α from the plasma membranes of astrocytes and likely neurons, thereby (i) obstructing the amyloidogenesis from APP and hence the cerebral accumulation of neurotoxic soluble Aβ~42~-os and fibrillar Aβ~42~ polymers, and (ii) abating the noxious neuronal hyperexcitability *via* sAPP-α•GABA~B~R1a signaling; (B) suppress the surplus synthesis and exosomal intrabrain dissemination of neurotoxic p-Tau-os and the consequent hypertoxic effects elicited by combined actions of the Aβ~42~-os/p-Tau-os duet ([@B162]; [@B64]); (C) reduce the increased synthesis and secretion of neurotoxic amounts of NO, VEGF-A, and likely other neurotoxic agents; (D) suppress any other harmful effects elicited by Aβ•CaSR signaling in oligodendrocytes, microglia, cerebrovascular cells of any kind; and (E) safeguard the blood--brain barrier (BBB) functional integrity. The above *in vitro* results also indicate that NAM efficacy persists notwithstanding a continued presence of soluble Aβ-os, fibrillar Aβs, and p-Tau-os ([@B64]; [@B65]; [@B66]). Therefore, it is likely that CaSR NAMS could safeguard *in vivo*, as they do *in vitro* ([@B7]), the viability and functions of the cortical human neurons preserving the integrity of critical cognition-essential upper cerebral cortical regions ([@B67]; [@B195]; [@B16]). In brief, CaSR NAMs would uphold the patients' ability to record and recover memories and to deal with their daily needs. Most important, the relatively cheap to synthesize CaSR NAMs appears to be the so far unique class of anti-AD therapeutics capable of concurrently targeting the multiple noxious effects triggered by pathological Aβs•CaSR signaling in human neurons, astrocytes, and the other brain cell types ([@B62]; [@B86]; [@B7]; [@B88]; [@B89]; [@B63]).

Ischemic neuronal injury is known to locally generate Aβs surpluses ([@B161]). More recent studies showed that the intraventricular administration of CaSR NAMs did decrease the death of neurons in the cortical *penumbra* zone of animal models of ischemia/hypoxia/stroke by effectively suppressing the concurrent *acute* increase in the local Aβ-os production ([@B180]; [@B13]). These results further strengthen the idea that pathological Aβ•CaSR signaling is crucially involved in both acute (ischemia/stroke) and chronic (AD) conditions causing neuronal death ([@B7]; [@B89]; [@B63]).

*Fyn* kinase inhibitor Saracatinib (AZD0530) and NMDAR inhibitors Memantine and Nitromemantine were endorsed as drugs to counteract the neurotoxicity driven by the extracellular accumulation of Aβ~42~-os ([@B174]). However, CaSR NAMs act on Aβ•CaSR signaling well upstream of *Fyn* and NMDARs. In addition, CaSR NAMs obstruct any cytotoxic effects and likely also any impediments to proliferation and differentiation of neural stem cells in the dentate gyrus subgranular zone ([@B321]).

Concerning their most salient pharmacological characteristics, because of their lipid-soluble chemical structures and limited numbers of electrical charges, CaSR NAMs traverse the BBB. They can be administered by any route: hitherto the oral route has been the preferred one for clinical trials. Rodents could endure NAM NPS 2143 administration with no serious off-target effects being reported ([@B230]; [@B180]). During the failed phase I and phase II clinical trials assessing NAMs antiosteoporosis activity, human subjects also satisfactorily tolerated the administration of novel NPS 2143 derivatives, which affected PTH release less intensely (no record was taken concerning any brain-related effects). In general, the safety data collected from the clinical trials of CaSR NAMs did not record any major side-effect. Obviously, the calcemia levels had to be checked periodically due to NAM-elicited increases in plasma PTH levels ([@B233]).

Conclusions {#s6}
===========

This survey\--necessarily short given the huge amount of literature concerning this verily fascinating topic\--leads us to several closing considerations. First and foremost, a lot of data from AD-model animals had to be forcibly mentioned because analogous human data are not available. Therefore, there is still quite a lot to discover and learn about the physiological roles of family C GPRS particularly in relation to human CNS and other viscera. Second, it is undeniable that some of these GPCRs could play central roles on human AD. Our work has been mainly, but not exclusively, based upon the experimental exploitation of human cortical astrocyte cultures and has focused on the pivotal role pathological Aβ•CaSR signaling exerts on the onset and progression of AD and on the potentially beneficial therapeutic effects CaSR NAMs could exert in LOAD/SAD patients. The interactions of CaSR heterodimers with other family C GPCRs, e.g. GABA~B~Rs and group I mGluRs, still constitute a mostly unexplored field of endeavor and their impact on AD onset and progression (if any) needs to be clarified. Notably, even in the gene mutations-driven EOFAD, CaSR NAMs could bring to bear mitigating and life-lengthening upshots by suppressing the additional aggravating consequences brought about by the concurrent Aβ•CaSR signaling adding up to those stemming from the mutated genes. Third, any possible AD-promoting effects of CaSR PAMs (calcimimetics) in humans should be thoroughly investigated since in our preclinical *in vitro* AD model PAM NPS R-568 significantly increased Aβ~42~/Aβ~42~-os release from untransformed human adult cortical astrocytes ([@B7]). Fourth, we wish to add a last comment about CaSR NAMs as candidate therapeutics for human AD. For reasons pertaining to normal physiology, CaSR NAMs failed their initial task as antiosteoporosis therapeutics ([@B231]; [@B232]; [@B233]; [@B234]). Moreover, the induction of a mild hypercalcemia by CaSR NAMs has been a bit too much stressed as "hyperparathyroidism" creating a prejudice against their use in humans. Nevertheless, one should remember that no drug is devoid of unwanted and/or off-target effects: the chemotherapeutics administered to oncological patients are a striking example of this. Therefore, CaSR NAMs' rather slight off-target effects, chiefly the mild controllable hypercalcemia, should be objectively weighed against CaSR NAMs' crucial capability of averting the worsening loss of memories and cognitive abilities, including recognition of the self, and the later unavoidable demise AD would inexorably deliver.
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